Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(6.69) per share which beat the analyst consensus estimate of $(7.54) by 11.27 percent. This is a 50 percent increase over losses of $(13.38) per share from the same period last year. The company reported quarterly sales of $28.520 million which beat the analyst consensus estimate of $26.838 million by 6.27 percent. This is a 298.16 percent increase over sales of $7.163 million the same period last year.